September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
TGF-β2 Perturbation of the Kallikrein-Kinin System in Human Trabecular Meshwork Cells
Author Affiliations & Notes
  • Jonathan Lautz
    Program in Neuroscience, Loyola University Chicago, Hines, Illinois, United States
    Research Service, Edward Hines Jr. VA Hospital, Hines, Illinois, United States
  • Cynthia Lynn Pervan
    Research Service, Edward Hines Jr. VA Hospital, Hines, Illinois, United States
    Ophthalmology, Loyola University Chicago, Maywood, Illinois, United States
  • Evan B Stubbs
    Research Service, Edward Hines Jr. VA Hospital, Hines, Illinois, United States
    Ophthalmology, Loyola University Chicago, Maywood, Illinois, United States
  • Footnotes
    Commercial Relationships   Jonathan Lautz, None; Cynthia Pervan, None; Evan Stubbs, None
  • Footnotes
    Support  Supported by the Dept. of Veterans Affairs, the Illinois Society for the Prevention of Blindness, the Midwest Eye-Banks, and the Richard A. Peritt Charitable Foundation.
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 4698. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Jonathan Lautz, Cynthia Lynn Pervan, Evan B Stubbs; TGF-β2 Perturbation of the Kallikrein-Kinin System in Human Trabecular Meshwork Cells
      . Invest. Ophthalmol. Vis. Sci. 2016;57(12):4698.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : In healthy eyes, intraocular pressure (IOP) is maintained through balanced production and outflow of aqueous humor (AH). Increased resistance to AH outflow is a major contributor of aberrant elevation of IOP. TGF-β2, a pro-fibrotic cytokine, is markedly elevated in AH of patients with POAG. The mechanism by which TGF-β2 promotes pathological elevation of IOP remains elusive, but may involve perturbation of the kallikrein-kinin system. Bradykinin (BK), a key mediator of the kinin system and a potent vasodilator, is produced locally within the eye. BK receptors subtypes have similarly been localized to ocular tissues. Activation of the BK B2-receptor lowers IOP in ocular hypertensive non-human primates. Here, we investigated the relationship between TGF-β2 and BK receptor expression and signaling in primary and transformed human trabecular meshwork (TM) cells.

Methods : Primary or transformed human TM cells were conditioned overnight in serum-free media and incubated in the absence or presence of TGF-β2 (5 ng/ml). Canonical TGF-β2 signaling was blocked by siRNA targeted knockdown of Smad2 or Smad3. Rho GTPase signaling was blocked by pretreatment with exoenzyme C3 transferase. De novo transcription was inhibited by co-treatment with actinomycin D. Relative changes in BK receptor mRNA and protein content were quantified by qRT-PCR and immunoblot, respectively.

Results : Porcine anterior segments chronically perfused with TGF-β2 exhibited a sustained increase in IOP compared to vehicle-treated matched segments. Quiescent TM cells expressed measurable levels of bradykinin receptor mRNA and protein. TM cells cultured in the presence of TGF-β2 exhibited a marked reduction in BK receptor expression in a time dependent manner. siRNA-targeted knockdown of Smad3, but not Smad2, prevented TGF-β2 mediated attenuation of BK receptor mRNA and protein expression. In contrast, disrupting the non-canonical Rho GTPase signaling pathway with exoenzyme C3 transferase had no effect on TGF-β2 mediated attenuation of BK receptor expression. TGF-β2 mediated decreases in BK mRNA content were not altered in the presence of actinomycin D.

Conclusions : Constitutive expression of bradykinin receptors in human TM cells is markedly attenuated by TGF-β2. Elevated content of TGF-β2 in the AH of POAG patients may elevate IOP, in part, by attenuating constitutive B2 receptor expression within the conventional outflow pathway.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×